2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
5
Neoplasms, Plasma Cell
3
Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Leukemia
2
Infections
2
Hematologic Neoplasms
2
Urologic Neoplasms
1
Neuromyelitis Optica
1
Neuroblastoma
1
Myelitis, Transverse
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Limbic Encephalitis
1
Immunoglobulin Light-chain Amyloidosis
1
Epilepsy
1
Epilepsies, Partial
1
Drug Resistant Epilepsy
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Autoimmune Diseases of the Nervous System
1
Autoimmune Diseases
1
Interventions
eculizumab
3
ublituximab
1
ravulizumab
1
Sugars
1
Rituximab
1
Plasma Exchange
1
OM 89
1
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
1
Mitoxantrone
1
LFB-R603
1
Interferon beta-1a
1
Immunoglobulins, Intravenous
1
Blood Specimen Collection
1
Adrenal Cortex Hormones
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelitis, Transverse
×
Immunoglobulins, Intravenous
×
Clear all
NCT02398994
2016-07-20
STRIVE
Guy's and St Thomas' NHS Foundation Trust
Phase 3
Terminated
2 enrolled